###begin article-title 0
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases
###end article-title 0
###begin p 1
###xml 21 24 18 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 387 390 375 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 569 572 551 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 722 725 701 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 830 833 806 809 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1104 1107 1077 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1313 1316 1283 1286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1379 1380 1346 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1377 1380 1344 1347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 1552 1555 1513 1516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 664 669 <span type="species:ncbi:10090">mouse</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 1124 1132 <span type="species:ncbi:9606">patients</span>
###xml 1266 1270 <span type="species:ncbi:10090">mice</span>
The presence of AbetapE3 (N-terminal truncated Abeta starting with pyroglutamate) in Alzheimer's disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of Abeta peptides in senile plaques of AD brains. This was later confirmed by other reports investigating AD and Down's syndrome postmortem brain tissue. Importantly, AbetapE3 has a higher aggregation propensity, and stability, and shows an increased toxicity compared to full-length Abeta. We have recently shown that intraneuronal accumulation of AbetapE3 peptides induces a severe neuron loss and an associated neurological phenotype in the TBA2 mouse model for AD. Given the increasing interest in AbetapE3, we have generated two novel monoclonal antibodies which were characterized as highly specific for AbetapE3 peptides and herein used to analyze plaque deposition in APP/PS1KI mice, an AD model with severe neuron loss and learning deficits. This was compared with the plaque pattern present in brain tissue from sporadic and familial AD cases. Abundant plaques positive for AbetapE3 were present in patients with sporadic AD and familial AD including those carrying mutations in APP (arctic and Swedish) and PS1. Interestingly, in APP/PS1KI mice we observed a continuous increase in AbetapE3 plaque load with increasing age, while the density for Abeta1-x plaques declined with aging. We therefore assume that, in particular, the peptides starting with position 1 of Abeta are N-truncated as disease progresses, and that, AbetapE3 positive plaques are resistant to age-dependent degradation likely due to their high stability and propensity to aggregate.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 458 462 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">1998</xref>
###xml 775 780 754 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1985a</xref>
###xml 782 783 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">b</xref>
###xml 989 993 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1986</xref>
###xml 1009 1013 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">1986</xref>
###xml 1037 1040 1013 1016 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1311 1315 1278 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">1992</xref>
###xml 1430 1433 1391 1394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1449 1453 1410 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">1995</xref>
###xml 1477 1480 1435 1438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1681 1685 1636 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2006</xref>
###xml 1703 1707 1658 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2000</xref>
###xml 1723 1727 1678 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1998</xref>
###xml 1745 1749 1700 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1996</xref>
###xml 1762 1766 1717 1721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">1997</xref>
###xml 1768 1772 1723 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2001</xref>
###xml 1791 1795 1746 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2005</xref>
###xml 1812 1816 1767 1771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2005</xref>
###xml 1818 1822 1773 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2007</xref>
###xml 1837 1841 1792 1796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">1997</xref>
###xml 1856 1860 1811 1815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">1996</xref>
###xml 1878 1882 1833 1837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">1998</xref>
###xml 1898 1902 1853 1857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2007</xref>
###xml 1279 1284 <span type="species:ncbi:9606">human</span>
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques composed of amyloid-beta (Abeta) surrounded by dystrophic neurites and neurofibrillary tangles. The discovery that certain early-onset familial forms of AD may be caused by an enhanced production of Abeta peptides have led to the hypothesis that amyloidogenic Abeta is intimately involved in the AD pathogenic process (Selkoe 1998). Besides Abeta peptides starting with an aspartate at position 1, a variety of different N-truncated Abeta peptides have been identified in AD brains. Ragged peptides with a major species including those beginning with phenylalanine at position 4 of Abeta have been reported as early as 1985 by Masters et al. (1985a, b)). In contrast, no N-terminal sequence could be obtained from cores purified in a sodium dodecyl sulfate-containing buffer, which led to the assumption that the N-terminus could be blocked (Gorevic et al. 1986; Selkoe et al. 1986). The presence of AbetapE3 (N-terminal truncated Abeta starting with pyroglutamate) in AD brain was subsequently shown using mass spectrometry of purified Abeta peptides, explaining at least partially initial difficulties in sequencing Abeta peptides purified from human brain tissue (Mori et al. 1992). The authors reported that only 10-15% of the total Abeta isolated by this method begins at position 3 with AbetapE3. Saido et al. (1995) then showed that AbetapE3 represents a dominant fraction of Abeta peptides in senile plaques of AD brains. This was later confirmed by other reports investigating AD and Down's syndrome postmortem brain tissue (Guntert et al. 2006; Harigaya et al. 2000; Hosoda et al. 1998; Iwatsubo et al. 1996; Kuo et al. 1997, 2001; Miravalle et al. 2005; Piccini et al. 2005, 2007; Russo et al. 1997; Saido et al. 1996, Tekirian et al. 1998, Wegiel et al. 2007).
###end p 4
###begin p 5
###xml 111 115 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1995</xref>
###xml 132 137 129 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1985a</xref>
###xml 139 140 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">b</xref>
###xml 161 164 155 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 216 220 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1999</xref>
###xml 239 243 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2006</xref>
###xml 272 276 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1998</xref>
###xml 355 359 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2002</xref>
###xml 373 377 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2001</xref>
###xml 1277 1281 1250 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2002</xref>
###xml 1481 1485 1454 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2008</xref>
###xml 1517 1521 1490 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 1728 1734 1695 1701 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 1897 1898 1861 1862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1897 1904 1861 1868 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>x</italic>-40/42</sub>
###xml 2042 2046 2006 2010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 514 529 <span type="species:ncbi:10090">transgenic mice</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 782 787 <span type="species:ncbi:9606">human</span>
###xml 806 811 <span type="species:ncbi:10090">mouse</span>
###xml 877 882 <span type="species:ncbi:10090">mouse</span>
###xml 1578 1586 <span type="species:ncbi:9606">patients</span>
###xml 1770 1775 <span type="species:ncbi:10090">mouse</span>
###xml 1802 1812 <span type="species:ncbi:7227">Drosophila</span>
###xml 1854 1858 <span type="species:ncbi:10090">mice</span>
In general, N-terminal deletions in general enhance aggregation of beta-amyloid peptides in vitro (Pike et al. 1995; Masters et al. 1985a, b). Importantly, AbetapE3 has a higher aggregation propensity (He and Barrow 1999; Schilling et al. 2006), and stability (Kuo et al. 1998), and shows an increased toxicity compared to full-length Abeta (Russo et al. 2002). Ku et al. (2001) have used an integrated chemical and morphological comparison of the Abeta peptides and amyloid plaques present in the brains of APP23 transgenic mice and human AD patients. The lack of post-translational modifications such as N-terminal degradation, isomerization, racemization and pyroglutamyl formation of Abeta from APP23 mice provides an explanation for the differences in solubility of Abeta from human AD and transgenic mouse plaques. This group also demonstrated that in another transgenic mouse model (Tg2576), Abeta peptides lacked a pronounced N-terminal degradation, post-translational modifications and cross-linkages that were frequently observed in the compact Abeta peptide deposits found in AD brain. Thus, under in vivo conditions, truncated Abeta molecules appeared to be generated by hydrolysis at multiple sites rather than by postmortem N-terminal degradation (Kalback et al. 2002). Recently, it has been demonstrated that the N-terminal pE-formation can be catalyzed by glutaminyl cyclase (QC) which pharmacologically is interfered by a QC inhibitor, both in vitro (Cynis et al. 2008) and in vivo (Schilling et al. 2008). QC expression was found up-regulated in the cortex of patients with AD and correlated with the appearance of pE-modified Abeta. Oral application of a glutaminyl cyclase inhibitor resulted in reduced AbetapE3-42 burden in two different transgenic mouse models of AD and in a new Drosophila model. Interestingly, treatment of these mice was accompanied by reductions in Abetax-40/42, diminished plaque formation and gliosis, as well as improved performance in context memory and spatial learning tests (Schilling et al. 2008).
###end p 5
###begin p 6
###xml 277 281 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">1999</xref>
###xml 483 487 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">1999</xref>
###xml 534 538 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2005</xref>
###xml 555 559 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1998</xref>
###xml 575 579 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2006</xref>
###xml 598 602 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2002</xref>
###xml 743 747 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">1999</xref>
###xml 935 939 923 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2004</xref>
###xml 955 959 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">2004</xref>
###xml 1119 1123 1101 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2009</xref>
###xml 1131 1135 1113 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2002</xref>
###xml 1144 1148 1126 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">2001</xref>
###xml 1314 1318 1290 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1999</xref>
###xml 1335 1339 1311 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2000</xref>
###xml 1479 1483 1455 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">2004</xref>
###xml 1498 1502 1474 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">2000</xref>
###xml 1663 1667 1636 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2004</xref>
###xml 1709 1714 1682 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2008b</xref>
###xml 1763 1768 1736 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2008a</xref>
###xml 1963 1968 1936 1941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M233T</sub>
###xml 1976 1981 1949 1954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L235P</sub>
###xml 2074 2078 2047 2051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">2008</xref>
###xml 2121 2125 2094 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">2007</xref>
###xml 2312 2316 2282 2286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2009</xref>
###xml 2405 2409 2372 2376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">x-42</sub>
###xml 2433 2437 2400 2404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2004</xref>
###xml 2514 2517 2478 2481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 2683 2687 2647 2651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2009</xref>
###xml 106 121 <span type="species:ncbi:10090">transgenic mice</span>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 1783 1787 <span type="species:ncbi:10090">mice</span>
###xml 1810 1815 <span type="species:ncbi:9606">human</span>
###xml 1878 1884 <span type="species:ncbi:10090">murine</span>
###xml 1998 2002 <span type="species:ncbi:10090">mice</span>
###xml 2342 2347 <span type="species:ncbi:10090">mouse</span>
###xml 2469 2474 <span type="species:ncbi:10090">mouse</span>
A promising experimental approach to unravel the role of Abeta in AD pathology has been the generation of transgenic mice overexpressing the amyloid precursor protein (APP). All mouse models mimic the typical AD-like pathological deficits in synaptic transmission (Hsia et al. 1999), changes in behavior, differential glutamate responses and deficits in long-term potentiation. These characteristics are generally attributed to the overexpression of full-length APP (Moechars et al. 1999). Although learning deficits (Billings et al. 2005; Holcomb et al. 1998; Oakley et al. 2006; Puolivali et al. 2002) were evident in various APP models, the extent of Abeta-amyloid deposition did not correlate with the behavioral phenotype (Holcomb et al. 1999). In the past, extracellular Abeta has been regarded as the causative agent, whereas more recent evidence now points to toxic effects of Abeta in intracellular compartments (Tseng et al. 2004; Wirths et al. 2004). In addition, another concept proposes that the soluble oligomers and the beta-sheet containing amyloid fibrils are the toxic forms of Abeta (Harmeier et al. 2009; Klein 2002; Selkoe 2001). It has further been demonstrated that soluble oligomeric Abeta42, but not plaque-associated Abeta, correlates best with cognitive dysfunction in AD (McLean et al. 1999; Naslund et al. 2000). Oligomers are formed preferentially intracellularly within neuronal processes and synapses rather than extracellularly (Takahashi et al. 2004; Walsh et al. 2000). Previously, we have reported that intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the hippocampus (Casas et al. 2004), the frontal cortex (Christensen et al. 2008b) and the cholinergic system (Christensen et al. 2008a) of APP/PS1KI mice expressing transgenic human mutant APP751 including the Swedish and London mutations on a murine knock-in (KI) Presenilin 1 (PS1) background with two FAD-linked mutations (PS1M233T and PS1L235P). The APP/PS1KI mice exhibit robust learning deficits at the age of 6 months (Wirths et al. 2008), age-dependent axonopathy (Wirths et al. 2007), neuron loss in hippocampus CA1 together with synaptic deficits, and hippocampus atrophy coinciding with intraneuronal aggregation of N-terminal modified Abeta variants (Breyhan et al. 2009). Notably, the APP/PS1KI mouse model exhibits a large heterogeneity of N-truncated Abetax-42 variants (Casas et al. 2004). Recently, we generated a new mouse model expressing only N-truncated AbetapE3 in neurons, and demonstrated for the first time that this peptide is neurotoxic in vivo inducing neuron loss and an associated neurological phenotype (Wirths et al. 2009).
###end p 6
###begin p 7
###xml 38 41 35 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 149 152 143 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
Given the increasing interest in AbetapE3, we have generated two novel monoclonal antibodies which we have characterized as highly specific for AbetapE3 peptides and herein used to analyze plaque deposition in APP/PS1KI mice, an AD model with severe neuron loss and learning deficits, and compared this pattern with that present in brain tissue from sporadic and familial AD cases.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Antibodies
###end title 9
###begin p 10
###xml 193 197 <span type="species:ncbi:10090">mice</span>
Two novel antibodies 1-57 and 2-48 against N-terminal truncated Abeta starting with pyroglutamate (pGlu, pE) were generated by Synaptic Systems (Goettingen, Germany) by immunizing three Balb/c mice with a KLH-coupled pyroglutamate-Abeta-peptide with the peptide pEFRHD-C. After preparation of the lymph nodes, cells were fused with the myeloma cell line P3-x63-Ag8. The hybridoma supernatants of mixed clones were screened by ELISA and subcloned. The monoclonal antibodies 1-57 (IgG2b) and 2-48 (IgG1) were selected and further characterized for their specificity and affinity (see below). Other monoclonal anti-Abeta antibodies used for comparison are 4G8 (Abeta epitope 17-24; Covance), HJ5.1 (Abeta 13-28, courtesy of Hong Jiang and David Holtzman) and Abeta[N] (IBL, Hamburg, Germany).
###end p 10
###begin title 11
Surface plasmon resonance analysis (BIAcore)
###end title 11
###begin p 12
###xml 179 183 173 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 190 194 181 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-38</sub>
###xml 201 207 189 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 377 381 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2009</xref>
To obtain affinity data, a BIAcore3000 system (GE Healthcare, Uppsala, Sweden) with the BIAcontrol software (Version 4.1) was used. Abeta peptides (PSL, Heidelberg, Germany; Abeta1-38, Abeta3-38, AbetapE3-38) were solubilized and monomerized in 50% formic acid, lyophilized, and re-solubilized in 0.12% ammonia to obtain stock solutions of 1 mug/mul [see also (Harmeier et al. 2009)]. The Abeta peptides were then immobilized by amine coupling (Amine Coupling Kit, GE Healthcare, Uppsala, Sweden) to CM5-chips at pH 4.5 after preparing dilutions (final peptide concentrations were 20 mug/ml) in coupling buffer (10 mM NaAcetate pH 4.5), as running buffer HBS-EP (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0,005% P20) was used. The monoclonal antibodies 1-57 and 2-48 were diluted in running buffer and tested in a concentration range from 1 to 35 mug/ml at flow rates of 15 or 20 mul/min, respectively. Injection times varied from 5 to 20 min. The antibodies Abeta[N] (IBL, Hamburg, Germany) and 4G8 (Covance, USA) were used at concentrations of 10 mug/ml. The chip surface was regenerated after each antibody injection by a 90 s pulse injection with buffer containing 8 M urea at a flow rate of 100 mul/min. Binding curves were evaluated with the BIA evaluation software (Version 4.1). All chemicals were obtained from Roth (Karlsruhe, Germany) except for HEPES (Sigma-Aldrich, Munchen, Germany) and P20 (GE Healthcare, Uppsala, Sweden).
###end p 12
###begin title 13
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice
###end title 13
###begin p 14
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2004</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 200 206 <span type="species:ncbi:10090">murine</span>
###xml 231 237 <span type="species:ncbi:10090">murine</span>
###xml 337 342 <span type="species:ncbi:10090">mouse</span>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
The generation of APP/PS1KI mice has been described previously (Casas et al. 2004). In brief, human mutant APP751 containing the Swedish and London mutations is overexpressed under the control of the murine Thy-1 promoter, whereas murine PS1 with the M233T and L235P FAD-linked mutations is expressed under the control of the endogenous mouse PS1 promoter. APP/PS1KI mice were a generous gift of Dr. Laurent Pradier, Sanofi-Aventis, France. The mice were backcrossed for more than 10 generations on a C57BL/6J genetic background. All animals were handled according to the German guidelines for animal care. All research involving animals have been conducted according to guidelines of the German animal protection law. According to that the local committee for animal welfare at the University Medicine of Goettingen approved the experiments before the mice were killed.
###end p 14
###begin title 15
Immunohistochemistry on paraffin sections
###end title 15
###begin p 16
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 887 891 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">2002</xref>
###xml 1009 1010 996 997 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1011 1012 998 999 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1802 1809 1782 1789 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1809 1955 1789 1935 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Demographic data of the human specimen, semi-quantitative plaque load assessment, vessel pathology (congophilic angiopathy, CAA) and Braak staging</p>
###xml 1809 1955 1789 1935 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Demographic data of the human specimen, semi-quantitative plaque load assessment, vessel pathology (congophilic angiopathy, CAA) and Braak staging</p></caption>
###xml 1955 1955 1935 1935 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 1955 1958 1935 1938 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Sex</th>
###xml 1958 1961 1938 1941 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Age</th>
###xml 1961 1972 1941 1952 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Plaque load</th>
###xml 1972 1975 1952 1955 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">CAA</th>
###xml 1975 1986 1955 1966 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Braak stage</th>
###xml 1955 1986 1935 1966 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2"/><th align="left" rowspan="2">Sex</th><th align="left" rowspan="2">Age</th><th align="left" colspan="3">Plaque load</th><th align="left" rowspan="2">CAA</th><th align="left" rowspan="2">Braak stage</th></tr>
###xml 1986 1990 1966 1970 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2-48</th>
###xml 1990 1993 1970 1973 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4G8</th>
###xml 1993 2001 1973 1978 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A&#946;[N]</th>
###xml 1986 2001 1966 1978 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">2-48</th><th align="left">4G8</th><th align="left">A&#946;[N]</th></tr>
###xml 1955 2001 1935 1978 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Sex</th><th align="left" rowspan="2">Age</th><th align="left" colspan="3">Plaque load</th><th align="left" rowspan="2">CAA</th><th align="left" rowspan="2">Braak stage</th></tr><tr><th align="left">2-48</th><th align="left">4G8</th><th align="left">A&#946;[N]</th></tr></thead>
###xml 2001 2010 1978 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control 1</td>
###xml 2010 2011 1987 1988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2011 2013 1988 1990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">74</td>
###xml 2013 2014 1990 1991 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2014 2015 1991 1992 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2015 2018 1992 1995 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2018 2028 1995 1996 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2028 2031 1996 1999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">III</td>
###xml 2001 2031 1978 1999 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Control 1</td><td align="left">M</td><td align="left">74</td><td align="left">+</td><td align="left">+</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">III</td></tr>
###xml 2031 2040 1999 2008 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control 2</td>
###xml 2040 2041 2008 2009 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2041 2043 2009 2011 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">82</td>
###xml 2043 2044 2011 2012 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2044 2045 2012 2013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2045 2046 2013 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2046 2047 2014 2015 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2047 2048 2015 2016 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 2031 2048 1999 2016 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Control 2</td><td align="left">F</td><td align="left">82</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">I</td></tr>
###xml 2048 2057 2016 2025 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control 3</td>
###xml 2057 2058 2025 2026 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2058 2060 2026 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">73</td>
###xml 2060 2061 2028 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2061 2062 2029 2030 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2062 2063 2030 2031 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2063 2073 2031 2032 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2073 2074 2032 2033 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 2048 2074 2016 2033 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Control 3</td><td align="left">F</td><td align="left">73</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">I</td></tr>
###xml 2074 2083 2033 2042 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control 4</td>
###xml 2083 2084 2042 2043 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2084 2086 2043 2045 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">79</td>
###xml 2086 2088 2045 2047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2088 2090 2047 2049 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2090 2091 2049 2050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2091 2101 2050 2051 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2101 2103 2051 2053 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">II</td>
###xml 2074 2103 2033 2053 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Control 4</td><td align="left">F</td><td align="left">79</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">II</td></tr>
###xml 2103 2112 2053 2062 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control 5</td>
###xml 2112 2113 2062 2063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2113 2115 2063 2065 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">70</td>
###xml 2115 2117 2065 2067 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2117 2120 2067 2070 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2120 2121 2070 2071 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2121 2122 2071 2072 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2122 2123 2072 2073 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2103 2123 2053 2073 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Control 5</td><td align="left">M</td><td align="left">70</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">0</td></tr>
###xml 2123 2132 2073 2082 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control 6</td>
###xml 2132 2133 2082 2083 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2133 2135 2083 2085 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">73</td>
###xml 2135 2137 2085 2087 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2137 2139 2087 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2139 2142 2089 2092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2142 2143 2092 2093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2143 2144 2093 2094 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2123 2144 2073 2094 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Control 6</td><td align="left">F</td><td align="left">73</td><td align="left">++</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">0</td></tr>
###xml 2144 2148 2094 2098 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 1</td>
###xml 2148 2149 2098 2099 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2149 2151 2099 2101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">72</td>
###xml 2151 2152 2101 2102 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2152 2154 2102 2104 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2154 2157 2104 2107 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2157 2158 2107 2108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2158 2160 2108 2110 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VI</td>
###xml 2144 2160 2094 2110 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 1</td><td align="left">M</td><td align="left">72</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">VI</td></tr>
###xml 2160 2164 2110 2114 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 2</td>
###xml 2164 2165 2114 2115 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2165 2167 2115 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">70</td>
###xml 2167 2170 2117 2120 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2170 2173 2120 2123 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2173 2176 2123 2126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2176 2186 2126 2127 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2186 2187 2127 2128 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">V</td>
###xml 2160 2187 2110 2128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 2</td><td align="left">M</td><td align="left">70</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">V</td></tr>
###xml 2187 2191 2128 2132 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 3</td>
###xml 2191 2192 2132 2133 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2192 2194 2133 2135 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78</td>
###xml 2194 2195 2135 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2195 2197 2136 2138 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2197 2200 2138 2141 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2200 2210 2141 2142 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2210 2212 2142 2144 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2187 2212 2128 2144 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 3</td><td align="left">M</td><td align="left">78</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr>
###xml 2212 2216 2144 2148 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 4</td>
###xml 2216 2217 2148 2149 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2217 2219 2149 2151 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60</td>
###xml 2219 2222 2151 2154 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2222 2225 2154 2157 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2225 2226 2157 2158 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2226 2227 2158 2159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2227 2229 2159 2161 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VI</td>
###xml 2212 2229 2144 2161 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 4</td><td align="left">M</td><td align="left">60</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr>
###xml 2229 2233 2161 2165 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 5</td>
###xml 2233 2234 2165 2166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2234 2236 2166 2168 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">93</td>
###xml 2236 2237 2168 2169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2237 2238 2169 2170 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2238 2239 2170 2171 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2239 2249 2171 2172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2249 2251 2172 2174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2229 2251 2161 2174 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 5</td><td align="left">M</td><td align="left">93</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">IV</td></tr>
###xml 2251 2255 2174 2178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 6</td>
###xml 2255 2256 2178 2179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2256 2258 2179 2181 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64</td>
###xml 2258 2262 2181 2185 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+/++</td>
###xml 2262 2264 2185 2187 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2264 2265 2187 2188 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2265 2275 2188 2189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2275 2277 2189 2191 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VI</td>
###xml 2251 2277 2174 2191 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 6</td><td align="left">M</td><td align="left">64</td><td align="left">+/++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">VI</td></tr>
###xml 2277 2281 2191 2195 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 7</td>
###xml 2281 2282 2195 2196 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2282 2284 2196 2198 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">77</td>
###xml 2284 2286 2198 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2286 2289 2200 2203 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2289 2290 2203 2204 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2290 2291 2204 2205 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2291 2293 2205 2207 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VI</td>
###xml 2277 2293 2191 2207 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 7</td><td align="left">F</td><td align="left">77</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr>
###xml 2293 2297 2207 2211 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 8</td>
###xml 2297 2298 2211 2212 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2298 2300 2212 2214 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">81</td>
###xml 2300 2302 2214 2216 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2302 2305 2216 2219 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2305 2306 2219 2220 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2306 2307 2220 2221 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2307 2309 2221 2223 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2293 2309 2207 2223 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 8</td><td align="left">F</td><td align="left">81</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr>
###xml 2309 2313 2223 2227 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 9</td>
###xml 2313 2314 2227 2228 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2314 2316 2228 2230 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78</td>
###xml 2316 2319 2230 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2319 2322 2233 2236 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2322 2323 2236 2237 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+</td>
###xml 2323 2324 2237 2238 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2324 2326 2238 2240 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2309 2326 2223 2240 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 9</td><td align="left">F</td><td align="left">78</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr>
###xml 2326 2331 2240 2245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 10</td>
###xml 2331 2332 2245 2246 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2332 2334 2246 2248 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64</td>
###xml 2334 2337 2248 2251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2337 2339 2251 2253 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">++</td>
###xml 2339 2340 2253 2254 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2340 2341 2254 2255 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2341 2344 2255 2258 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">III</td>
###xml 2326 2344 2240 2258 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 10</td><td align="left">F</td><td align="left">64</td><td align="left">(+)</td><td align="left">++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">III</td></tr>
###xml 2344 2349 2258 2263 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 11</td>
###xml 2349 2350 2263 2264 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2350 2352 2264 2266 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">88</td>
###xml 2352 2355 2266 2269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2355 2358 2269 2272 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2358 2359 2272 2273 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2359 2369 2273 2274 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2369 2371 2274 2276 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2344 2371 2258 2276 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 11</td><td align="left">F</td><td align="left">88</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">IV</td></tr>
###xml 2371 2376 2276 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 12</td>
###xml 2376 2377 2281 2282 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2377 2379 2282 2284 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">81</td>
###xml 2379 2382 2284 2287 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2382 2385 2287 2290 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2385 2388 2290 2293 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2388 2398 2293 2294 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2398 2400 2294 2296 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2371 2400 2276 2296 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 12</td><td align="left">M</td><td align="left">81</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">IV</td></tr>
###xml 2400 2405 2296 2301 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 13</td>
###xml 2405 2406 2301 2302 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2406 2408 2302 2304 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">84</td>
###xml 2408 2411 2304 2307 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2411 2414 2307 2310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2414 2415 2310 2311 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2415 2416 2311 2312 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;</td>
###xml 2416 2418 2312 2314 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2400 2418 2296 2314 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 13</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">IV</td></tr>
###xml 2418 2423 2314 2319 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD 14</td>
###xml 2423 2424 2319 2320 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2424 2426 2320 2322 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">84</td>
###xml 2426 2429 2322 2325 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2429 2432 2325 2328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2432 2435 2328 2331 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2435 2445 2331 2332 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2445 2447 2332 2334 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 2418 2447 2314 2334 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD 14</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr>
###xml 2447 2458 2334 2345 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FAD APP arc</td>
###xml 2458 2459 2345 2346 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2459 2461 2346 2348 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64</td>
###xml 2461 2464 2348 2351 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2464 2467 2351 2354 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2467 2471 2354 2358 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+/++</td>
###xml 2471 2481 2358 2359 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2481 2485 2359 2363 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.a.</td>
###xml 2447 2485 2334 2363 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">FAD APP arc</td><td align="left">M</td><td align="left">64</td><td align="left">+++</td><td align="left">+++</td><td align="left">+/++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr>
###xml 2485 2496 2363 2374 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FAD APP swe</td>
###xml 2496 2497 2374 2375 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 2497 2499 2375 2377 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">61</td>
###xml 2499 2502 2377 2380 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2502 2505 2380 2383 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2505 2508 2383 2386 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2508 2518 2386 2387 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2518 2522 2387 2391 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.a.</td>
###xml 2485 2522 2363 2391 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">FAD APP swe</td><td align="left">F</td><td align="left">61</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr>
###xml 2522 2535 2391 2404 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FAD PS1 P264L</td>
###xml 2535 2536 2404 2405 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 2536 2538 2405 2407 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">54</td>
###xml 2538 2541 2407 2410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2541 2544 2410 2413 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">+++</td>
###xml 2544 2547 2413 2416 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(+)</td>
###xml 2547 2557 2416 2417 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#10003;</td>
###xml 2557 2559 2417 2419 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VI</td>
###xml 2522 2559 2391 2419 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">FAD PS1 P264L</td><td align="left">M</td><td align="left">54</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">VI</td></tr>
###xml 2001 2559 1978 2419 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Control 1</td><td align="left">M</td><td align="left">74</td><td align="left">+</td><td align="left">+</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">III</td></tr><tr><td align="left">Control 2</td><td align="left">F</td><td align="left">82</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">I</td></tr><tr><td align="left">Control 3</td><td align="left">F</td><td align="left">73</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">I</td></tr><tr><td align="left">Control 4</td><td align="left">F</td><td align="left">79</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">II</td></tr><tr><td align="left">Control 5</td><td align="left">M</td><td align="left">70</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">0</td></tr><tr><td align="left">Control 6</td><td align="left">F</td><td align="left">73</td><td align="left">++</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">0</td></tr><tr><td align="left">AD 1</td><td align="left">M</td><td align="left">72</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 2</td><td align="left">M</td><td align="left">70</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">V</td></tr><tr><td align="left">AD 3</td><td align="left">M</td><td align="left">78</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 4</td><td align="left">M</td><td align="left">60</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 5</td><td align="left">M</td><td align="left">93</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 6</td><td align="left">M</td><td align="left">64</td><td align="left">+/++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">VI</td></tr><tr><td align="left">AD 7</td><td align="left">F</td><td align="left">77</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 8</td><td align="left">F</td><td align="left">81</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 9</td><td align="left">F</td><td align="left">78</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 10</td><td align="left">F</td><td align="left">64</td><td align="left">(+)</td><td align="left">++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">III</td></tr><tr><td align="left">AD 11</td><td align="left">F</td><td align="left">88</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 12</td><td align="left">M</td><td align="left">81</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 13</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 14</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">FAD APP arc</td><td align="left">M</td><td align="left">64</td><td align="left">+++</td><td align="left">+++</td><td align="left">+/++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr><tr><td align="left">FAD APP swe</td><td align="left">F</td><td align="left">61</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr><tr><td align="left">FAD PS1 P264L</td><td align="left">M</td><td align="left">54</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">VI</td></tr></tbody>
###xml 1955 2559 1935 2419 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Sex</th><th align="left" rowspan="2">Age</th><th align="left" colspan="3">Plaque load</th><th align="left" rowspan="2">CAA</th><th align="left" rowspan="2">Braak stage</th></tr><tr><th align="left">2-48</th><th align="left">4G8</th><th align="left">A&#946;[N]</th></tr></thead><tbody><tr><td align="left">Control 1</td><td align="left">M</td><td align="left">74</td><td align="left">+</td><td align="left">+</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">III</td></tr><tr><td align="left">Control 2</td><td align="left">F</td><td align="left">82</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">I</td></tr><tr><td align="left">Control 3</td><td align="left">F</td><td align="left">73</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">I</td></tr><tr><td align="left">Control 4</td><td align="left">F</td><td align="left">79</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">II</td></tr><tr><td align="left">Control 5</td><td align="left">M</td><td align="left">70</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">0</td></tr><tr><td align="left">Control 6</td><td align="left">F</td><td align="left">73</td><td align="left">++</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">0</td></tr><tr><td align="left">AD 1</td><td align="left">M</td><td align="left">72</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 2</td><td align="left">M</td><td align="left">70</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">V</td></tr><tr><td align="left">AD 3</td><td align="left">M</td><td align="left">78</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 4</td><td align="left">M</td><td align="left">60</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 5</td><td align="left">M</td><td align="left">93</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 6</td><td align="left">M</td><td align="left">64</td><td align="left">+/++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">VI</td></tr><tr><td align="left">AD 7</td><td align="left">F</td><td align="left">77</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 8</td><td align="left">F</td><td align="left">81</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 9</td><td align="left">F</td><td align="left">78</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 10</td><td align="left">F</td><td align="left">64</td><td align="left">(+)</td><td align="left">++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">III</td></tr><tr><td align="left">AD 11</td><td align="left">F</td><td align="left">88</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 12</td><td align="left">M</td><td align="left">81</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 13</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 14</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">FAD APP arc</td><td align="left">M</td><td align="left">64</td><td align="left">+++</td><td align="left">+++</td><td align="left">+/++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr><tr><td align="left">FAD APP swe</td><td align="left">F</td><td align="left">61</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr><tr><td align="left">FAD PS1 P264L</td><td align="left">M</td><td align="left">54</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">VI</td></tr></tbody></table>
###xml 2559 2851 2419 2699 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18">The three familial AD (FAD) patients harbored an APP Swedish mutation (APP swe), an APP arctic mutation (APP arc), and a Presenilin-1 mutation (FAD P264L). Most but not all cases also showed CAA. Antibodies: 4G8 (A&#946; 17-24), 2-48 (pGlu A&#946;) and A&#946;[N] (specific for A&#946; at position 1)</p>
###xml 2559 2851 2419 2699 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18">The three familial AD (FAD) patients harbored an APP Swedish mutation (APP swe), an APP arctic mutation (APP arc), and a Presenilin-1 mutation (FAD P264L). Most but not all cases also showed CAA. Antibodies: 4G8 (A&#946; 17-24), 2-48 (pGlu A&#946;) and A&#946;[N] (specific for A&#946; at position 1)</p></table-wrap-foot>
###xml 1802 2851 1782 2699 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Demographic data of the human specimen, semi-quantitative plaque load assessment, vessel pathology (congophilic angiopathy, CAA) and Braak staging</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Sex</th><th align="left" rowspan="2">Age</th><th align="left" colspan="3">Plaque load</th><th align="left" rowspan="2">CAA</th><th align="left" rowspan="2">Braak stage</th></tr><tr><th align="left">2-48</th><th align="left">4G8</th><th align="left">A&#946;[N]</th></tr></thead><tbody><tr><td align="left">Control 1</td><td align="left">M</td><td align="left">74</td><td align="left">+</td><td align="left">+</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">III</td></tr><tr><td align="left">Control 2</td><td align="left">F</td><td align="left">82</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">I</td></tr><tr><td align="left">Control 3</td><td align="left">F</td><td align="left">73</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">I</td></tr><tr><td align="left">Control 4</td><td align="left">F</td><td align="left">79</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">II</td></tr><tr><td align="left">Control 5</td><td align="left">M</td><td align="left">70</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">0</td></tr><tr><td align="left">Control 6</td><td align="left">F</td><td align="left">73</td><td align="left">++</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">0</td></tr><tr><td align="left">AD 1</td><td align="left">M</td><td align="left">72</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 2</td><td align="left">M</td><td align="left">70</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">V</td></tr><tr><td align="left">AD 3</td><td align="left">M</td><td align="left">78</td><td align="left">+</td><td align="left">++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 4</td><td align="left">M</td><td align="left">60</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 5</td><td align="left">M</td><td align="left">93</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 6</td><td align="left">M</td><td align="left">64</td><td align="left">+/++</td><td align="left">++</td><td align="left">+</td><td align="left">&#10003;</td><td align="left">VI</td></tr><tr><td align="left">AD 7</td><td align="left">F</td><td align="left">77</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">VI</td></tr><tr><td align="left">AD 8</td><td align="left">F</td><td align="left">81</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 9</td><td align="left">F</td><td align="left">78</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 10</td><td align="left">F</td><td align="left">64</td><td align="left">(+)</td><td align="left">++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">III</td></tr><tr><td align="left">AD 11</td><td align="left">F</td><td align="left">88</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 12</td><td align="left">M</td><td align="left">81</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">AD 13</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#8722;</td><td align="left">&#8722;</td><td align="left">IV</td></tr><tr><td align="left">AD 14</td><td align="left">F</td><td align="left">84</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">IV</td></tr><tr><td align="left">FAD APP arc</td><td align="left">M</td><td align="left">64</td><td align="left">+++</td><td align="left">+++</td><td align="left">+/++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr><tr><td align="left">FAD APP swe</td><td align="left">F</td><td align="left">61</td><td align="left">+++</td><td align="left">+++</td><td align="left">+++</td><td align="left">&#10003;</td><td align="left">n.a.</td></tr><tr><td align="left">FAD PS1 P264L</td><td align="left">M</td><td align="left">54</td><td align="left">+++</td><td align="left">+++</td><td align="left">(+)</td><td align="left">&#10003;</td><td align="left">VI</td></tr></tbody></table><table-wrap-foot><p textid="18">The three familial AD (FAD) patients harbored an APP Swedish mutation (APP swe), an APP arctic mutation (APP arc), and a Presenilin-1 mutation (FAD P264L). Most but not all cases also showed CAA. Antibodies: 4G8 (A&#946; 17-24), 2-48 (pGlu A&#946;) and A&#946;[N] (specific for A&#946; at position 1)</p></table-wrap-foot></table-wrap>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 575 579 <span type="species:ncbi:10090">Mice</span>
###xml 1264 1268 <span type="species:ncbi:9913">calf</span>
###xml 1833 1838 <span type="species:ncbi:9606">human</span>
###xml 2587 2595 <span type="species:ncbi:9606">patients</span>
Human brain samples from frontal cortex were obtained from (1) the Netherlands Brain Bank (NBB), Amsterdam, The Netherlands; (2) the APP Swedish and APP arctic FAD brain samples from Uppsala University, and the Presenilin-1 FAD brain samples from the Hopital del la Salpetriere, a generous gift of Prof. Dr. Charles Duyckaerts and Dr. Veronique Sazdovitch. We did not receive information of the cause of death and postmortem delay in all cases, therefore the information was not added to Table 1. Tissue was post-fixed in 4% buffered formalin at 4degreesC for several weeks. Mice were transcardially perfused with 4% PFA in PBS and brains were carefully dissected. Post-fixation was carried out in 4% buffered formalin at 4degreesC before the tissue was embedded in paraffin. Immunohistochemistry was performed on 4 mum sagittal paraffin sections, as described previously (Wirths et al. 2002). In brief, sections were deparaffinized in xylene and rehydrated in a series of ethanol. After treatment with 0.3% H2O2 in PBS to block endogenous peroxidases, antigen retrieval was achieved by boiling sections in 0.01 M citrate buffer pH 6.0, followed by 3 min incubation in 88% formic acid. Non-specific binding sites were blocked by treatment with skim milk and fetal calf serum in PBS, prior to the addition of the primary antibodies. Primary antibodies 4G8 (1 mug/ml), Abeta[N] (2 mug/ml); 2-48 (10 mug/ml) and 1-57 (10 mug/ml), were incubated overnight in a humid chamber at room temperature, followed by incubation with biotinylated secondary antibodies (DAKO, Glostrup, DK) before staining was visualized using the ABC method with Vectastain kit (Vector Laboratories, Burlingame, USA) and diaminobenzidine as chromogen providing a reddish brown color. Counterstaining was carried out with hematoxylin.Table 1Demographic data of the human specimen, semi-quantitative plaque load assessment, vessel pathology (congophilic angiopathy, CAA) and Braak stagingSexAgePlaque loadCAABraak stage2-484G8Abeta[N]Control 1M74++(+)check markIIIControl 2F82----IControl 3F73---check markIControl 4F79+++++check markIIControl 5M70++++++-0Control 6F73++++(+)-0AD 1M72+++(+)-VIAD 2M70+++++++++check markVAD 3M78+++(+)check markIVAD 4M60+++++++-VIAD 5M93+++check markIVAD 6M64+/+++++check markVIAD 7F77++++++-VIAD 8F81++++++-IVAD 9F78+++++++-IVAD 10F64(+)++--IIIAD 11F88++++++-check markIVAD 12M81+++++++++check markIVAD 13F84++++++--IVAD 14F84++++++(+)check markIVFAD APP arcM64+++++++/++check markn.a.FAD APP sweF61+++++++++check markn.a.FAD PS1 P264LM54++++++(+)check markVIThe three familial AD (FAD) patients harbored an APP Swedish mutation (APP swe), an APP arctic mutation (APP arc), and a Presenilin-1 mutation (FAD P264L). Most but not all cases also showed CAA. Antibodies: 4G8 (Abeta 17-24), 2-48 (pGlu Abeta) and Abeta[N] (specific for Abeta at position 1)
###end p 16
###begin p 17
###xml 24 29 <span type="species:ncbi:9606">human</span>
Demographic data of the human specimen, semi-quantitative plaque load assessment, vessel pathology (congophilic angiopathy, CAA) and Braak staging
###end p 17
###begin p 18
###xml 28 36 <span type="species:ncbi:9606">patients</span>
The three familial AD (FAD) patients harbored an APP Swedish mutation (APP swe), an APP arctic mutation (APP arc), and a Presenilin-1 mutation (FAD P264L). Most but not all cases also showed CAA. Antibodies: 4G8 (Abeta 17-24), 2-48 (pGlu Abeta) and Abeta[N] (specific for Abeta at position 1)
###end p 18
###begin title 19
Quantification of Abeta load
###end title 19
###begin p 20
For each tissue block, five paraffin-embedded sections, at least 25 mum apart from each other, were stained simultaneously with DAB as chromogen. The relative Abeta load was evaluated using an Olympus BX-51 microscope equipped with an Olympus DP-50 camera and the ImageJ software (NIH, USA). Representative pictures of 10x magnification were systematically captured from the cortex. The pictures were binarized to 8-bit black using ImageJ and white pictures and a fixed intensity threshold was applied defining the DAB staining. Measurements were performed for a percentage of the area covered by the Abeta DAB staining.
###end p 20
###begin title 21
Western blot
###end title 21
###begin p 22
###xml 24 28 21 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 35 39 29 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 46 53 37 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE11-42</sub>
###xml 63 69 51 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 890 895 <span type="species:ncbi:10090">mouse</span>
Peptides including Abeta1-42, Abeta3-42, AbetapE11-42 and AbetapE3-42 were purchased from Anaspec (San Jose, CA) and reconstituted in conditions specific to each peptide. For each Western blot, 10 ng of peptide was loaded per lane of a 12% Bis-Tris gel in MES buffer and run at 150 V for 1 h. The peptides were then transferred to 0.45 mum nitrocellulose for 1 h at 100 mA per membrane using wet transfer in Towbin buffer. Post-transfer, membranes were incubated in PBS, pH 9.0 at 95degreesC for 5 min, which allows for improved access to the antigen. Membranes were then blocked in 2%NFDM/PBS, pH 9.0 for 1 h at room temperature while gently mixing, before overnight incubation at 4degreesC using the primary antibody (1-57, 2-48 or HJ5.1) at 1 mug/ml in blocking buffer, again while gently mixing. Membranes were rinsed in PBS/0.05%Tween-20 (pH 9.0) three times for 5 min. Secondary anti-mouse IgG-HRP was applied in blocking conditions at a 1:10,000 dilution for 1 h at room temperature. Membranes were rinsed in PBS/0.05%Tween-20 (pH 9.0) three times for 10 min. The blots were developed using ECL Advance (GE Healthcare) by applying the chemiluminescent reagents for 1 min in reduced light conditions and then imaged on standard film emulsion.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 167 168 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 180 181 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 194 195 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Stereological quantifications were analyzed using two-way ANOVA followed by t tests. Data are presented as mean +/- SEM. Significance levels were given as follows: ***P < 0.001, **P < 0.01 and *P < 0.05. All statistical analysis was performed using GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego, CA, USA).
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
###xml 35 36 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 31 36 28 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-<italic>x</italic></sub>
Antibody staining against AbetapE3-x
###end title 26
###begin p 27
###xml 68 71 65 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 188 189 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 199 200 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 340 343 331 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 369 375 360 366 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 413 416 398 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 505 506 490 491 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 537 538 519 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 549 550 531 532 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 608 609 590 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 627 636 609 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 375 644 366 625 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Plaque staining with pGlu A&#946; (A&#946;<sub>pE3</sub>) antibodies in frontal cortex in sporadic AD brain. Plaques staining with antibody 4G8 (<bold>a</bold>), pGlu A&#946; antibodies 2-48 (<bold>b</bold>) and 1-57(<bold>c</bold>); but no staining in plaque-free healthy control tissue (<bold>d</bold>, 2-48 staining). <italic>Scale bar</italic> 100&#160;&#956;m</p>
###xml 375 644 366 625 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Plaque staining with pGlu A&#946; (A&#946;<sub>pE3</sub>) antibodies in frontal cortex in sporadic AD brain. Plaques staining with antibody 4G8 (<bold>a</bold>), pGlu A&#946; antibodies 2-48 (<bold>b</bold>) and 1-57(<bold>c</bold>); but no staining in plaque-free healthy control tissue (<bold>d</bold>, 2-48 staining). <italic>Scale bar</italic> 100&#160;&#956;m</p></caption>
###xml 644 644 625 625 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_314_Fig1_HTML" id="MO1"/>
###xml 369 644 360 625 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="28">Plaque staining with pGlu A&#946; (A&#946;<sub>pE3</sub>) antibodies in frontal cortex in sporadic AD brain. Plaques staining with antibody 4G8 (<bold>a</bold>), pGlu A&#946; antibodies 2-48 (<bold>b</bold>) and 1-57(<bold>c</bold>); but no staining in plaque-free healthy control tissue (<bold>d</bold>, 2-48 staining). <italic>Scale bar</italic> 100&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="702_2009_314_Fig1_HTML" id="MO1"/></fig>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
In order to characterize the staining pattern of the two novel AbetapE3 antibodies, formalin-fixed and paraffin-embedded cortical tissue sections from 14 patients with AD were used (Table 1). Figure 1 shows plaque staining in frontal cortex of sporadic AD with the Abeta antibody 4G8. There were no significant differences between the AbetapE3 antibodies 1-57 and 2-48.Fig. 1Plaque staining with pGlu Abeta (AbetapE3) antibodies in frontal cortex in sporadic AD brain. Plaques staining with antibody 4G8 (a), pGlu Abeta antibodies 2-48 (b) and 1-57(c); but no staining in plaque-free healthy control tissue (d, 2-48 staining). Scale bar 100 mum
###end p 27
###begin p 28
###xml 38 41 32 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 130 131 124 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 162 163 153 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 174 175 165 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 233 234 224 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 252 261 243 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
Plaque staining with pGlu Abeta (AbetapE3) antibodies in frontal cortex in sporadic AD brain. Plaques staining with antibody 4G8 (a), pGlu Abeta antibodies 2-48 (b) and 1-57(c); but no staining in plaque-free healthy control tissue (d, 2-48 staining). Scale bar 100 mum
###end p 28
###begin title 29
Surface plasmon resonance analysis of antibodies
###end title 29
###begin p 30
###xml 446 452 440 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 459 460 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 516 520 507 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-38</sub>
###xml 524 528 515 519 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 655 659 640 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 714 715 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 911 914 890 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1094 1095 1073 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1095 1096 1074 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D</sub>
###xml 1225 1231 1201 1207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 1232 1238 1208 1214 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1278 1281 1248 1251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1296 1297 1266 1267 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1352 1353 1322 1323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1390 1396 1357 1363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 1410 1414 1374 1378 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-38</sub>
###xml 1424 1428 1385 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 1431 1432 1392 1393 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1488 1492 1443 1447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 1503 1507 1455 1459 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-38</sub>
###xml 1516 1522 1465 1471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 1525 1526 1474 1475 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1557 1566 1503 1512 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3p(E)-42,</sub>
###xml 1580 1584 1523 1527 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 1591 1595 1531 1535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 1605 1614 1542 1551 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11p(E)-42</sub>
###xml 1639 1645 1576 1582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1</italic>
###xml 1651 1655 1585 1589 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 1657 1663 1591 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 2</italic>
###xml 1669 1673 1600 1604 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 1675 1681 1606 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 3</italic>
###xml 1687 1696 1615 1624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11p(E)-42</sub>
###xml 1698 1704 1626 1632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 4</italic>
###xml 1710 1718 1635 1643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3p(E)-42</sub>
###xml 1906 1914 1827 1835 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3p(E)-42</sub>
###xml 1921 1925 1839 1843 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 1932 1936 1847 1851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 1946 1955 1858 1867 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11p(E)-42</sub>
###xml 1238 1978 1214 1890 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Binding specificity of pGlu A&#946; (A&#946;<sub>pE3</sub>) antibodies. (<bold>a</bold>) Biacore analysis revealed that pGlu antibodies 2-48 (<bold>b</bold>) and 1-57 specifically bind to A&#946;<sub>pE3-38</sub>, not to A&#946;<sub>3-38</sub> and A&#946;<sub>1-38</sub>. (<bold>c</bold>) The commercial antibody A&#946;[N] recognizes only A&#946;<sub>1-38</sub>, not A&#946;<sub>3-38</sub> or A&#946;<sub>pE3-38</sub>. (<bold>d</bold>) 2-48 and 1-57 recognize A&#946;<sub>3p(E)-42,</sub> but not A&#946;<sub>1-42</sub>, A&#946;<sub>3-42</sub>, or A&#946;<sub>11p(E)-42</sub> under these conditions. <italic>Lane 1</italic> A&#946;<sub>1-42</sub>, <italic>Lane 2</italic> A&#946;<sub>3-42</sub>, <italic>Lane 3</italic> A&#946;<sub>11p(E)-42</sub>, <italic>Lane 4</italic> A&#946;<sub>3p(E)-42</sub>. 10&#160;ng per well of each peptide was loaded on 3 separate 12% Bis&#8211;Tris gels, transferred to nitrocellulose and blotted with 1&#160;&#956;g/ml of each primary antibody. 2-48 and 1-57 recognize A&#946;<sub>3p(E)-42</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>3-42</sub>, or A&#946;<sub>11p(E)-42</sub> under these conditions</p>
###xml 1238 1978 1214 1890 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Binding specificity of pGlu A&#946; (A&#946;<sub>pE3</sub>) antibodies. (<bold>a</bold>) Biacore analysis revealed that pGlu antibodies 2-48 (<bold>b</bold>) and 1-57 specifically bind to A&#946;<sub>pE3-38</sub>, not to A&#946;<sub>3-38</sub> and A&#946;<sub>1-38</sub>. (<bold>c</bold>) The commercial antibody A&#946;[N] recognizes only A&#946;<sub>1-38</sub>, not A&#946;<sub>3-38</sub> or A&#946;<sub>pE3-38</sub>. (<bold>d</bold>) 2-48 and 1-57 recognize A&#946;<sub>3p(E)-42,</sub> but not A&#946;<sub>1-42</sub>, A&#946;<sub>3-42</sub>, or A&#946;<sub>11p(E)-42</sub> under these conditions. <italic>Lane 1</italic> A&#946;<sub>1-42</sub>, <italic>Lane 2</italic> A&#946;<sub>3-42</sub>, <italic>Lane 3</italic> A&#946;<sub>11p(E)-42</sub>, <italic>Lane 4</italic> A&#946;<sub>3p(E)-42</sub>. 10&#160;ng per well of each peptide was loaded on 3 separate 12% Bis&#8211;Tris gels, transferred to nitrocellulose and blotted with 1&#160;&#956;g/ml of each primary antibody. 2-48 and 1-57 recognize A&#946;<sub>3p(E)-42</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>3-42</sub>, or A&#946;<sub>11p(E)-42</sub> under these conditions</p></caption>
###xml 1978 1978 1890 1890 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_314_Fig2_HTML" id="MO2"/>
###xml 1232 1978 1208 1890 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="31">Binding specificity of pGlu A&#946; (A&#946;<sub>pE3</sub>) antibodies. (<bold>a</bold>) Biacore analysis revealed that pGlu antibodies 2-48 (<bold>b</bold>) and 1-57 specifically bind to A&#946;<sub>pE3-38</sub>, not to A&#946;<sub>3-38</sub> and A&#946;<sub>1-38</sub>. (<bold>c</bold>) The commercial antibody A&#946;[N] recognizes only A&#946;<sub>1-38</sub>, not A&#946;<sub>3-38</sub> or A&#946;<sub>pE3-38</sub>. (<bold>d</bold>) 2-48 and 1-57 recognize A&#946;<sub>3p(E)-42,</sub> but not A&#946;<sub>1-42</sub>, A&#946;<sub>3-42</sub>, or A&#946;<sub>11p(E)-42</sub> under these conditions. <italic>Lane 1</italic> A&#946;<sub>1-42</sub>, <italic>Lane 2</italic> A&#946;<sub>3-42</sub>, <italic>Lane 3</italic> A&#946;<sub>11p(E)-42</sub>, <italic>Lane 4</italic> A&#946;<sub>3p(E)-42</sub>. 10&#160;ng per well of each peptide was loaded on 3 separate 12% Bis&#8211;Tris gels, transferred to nitrocellulose and blotted with 1&#160;&#956;g/ml of each primary antibody. 2-48 and 1-57 recognize A&#946;<sub>3p(E)-42</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>3-42</sub>, or A&#946;<sub>11p(E)-42</sub> under these conditions</p></caption><graphic position="anchor" xlink:href="702_2009_314_Fig2_HTML" id="MO2"/></fig>
The specificity and affinity of the antibodies used for immunohistochemical staining was determined with the help of surface plasmon resonance analyses (BIAcore). Equal amounts of the Abeta peptides pE3-38, 3-38, and 1-38 were immobilized to a sensor chip surface and various dilutions of the individual antibody were applied to quantify binding. The resulting sensorgrams clearly demonstrate an unequivocal specificity of 1-57 and 2-48 for AbetapE3-38 (Fig. 2a, b), while we could hardly detect any binding to Abeta3-38 or 1-38. In contrast to the pGlu-specific antibodies, the commercially available antibody Abeta[N] exhibited specific binding to Abeta1-38 when subjected to the respective sensor surface (Fig. 2c). Hence, this result implies that this antibody is highly suitable to reveal the presence and quantity also in brain tissue of full-length Abeta species compared to the shorter species and AbetapE3. To further characterize 1-57 and 2-48, the avidities of both antibodies were calculated from the steady state of binding activity at various tested concentrations. The resulting KD-values of 17.7 nM for 1-57 and 9.1 nM for 2-48 confirmed a very high affinity for both antibodies specifically recognizing AbetapE3-38.Fig. 2Binding specificity of pGlu Abeta (AbetapE3) antibodies. (a) Biacore analysis revealed that pGlu antibodies 2-48 (b) and 1-57 specifically bind to AbetapE3-38, not to Abeta3-38 and Abeta1-38. (c) The commercial antibody Abeta[N] recognizes only Abeta1-38, not Abeta3-38 or AbetapE3-38. (d) 2-48 and 1-57 recognize Abeta3p(E)-42, but not Abeta1-42, Abeta3-42, or Abeta11p(E)-42 under these conditions. Lane 1 Abeta1-42, Lane 2 Abeta3-42, Lane 3 Abeta11p(E)-42, Lane 4 Abeta3p(E)-42. 10 ng per well of each peptide was loaded on 3 separate 12% Bis-Tris gels, transferred to nitrocellulose and blotted with 1 mug/ml of each primary antibody. 2-48 and 1-57 recognize Abeta3p(E)-42, Abeta1-42, Abeta3-42, or Abeta11p(E)-42 under these conditions
###end p 30
###begin p 31
###xml 40 43 34 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 58 59 52 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 114 115 108 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 152 158 143 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 172 176 160 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-38</sub>
###xml 186 190 171 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 193 194 178 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 250 254 229 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-38</sub>
###xml 265 269 241 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-38</sub>
###xml 278 284 251 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-38</sub>
###xml 287 288 260 261 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 319 328 289 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3p(E)-42,</sub>
###xml 342 346 309 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 353 357 317 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 367 376 328 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11p(E)-42</sub>
###xml 401 407 362 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1</italic>
###xml 413 417 371 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 419 425 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 2</italic>
###xml 431 435 386 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 437 443 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 3</italic>
###xml 449 458 401 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11p(E)-42</sub>
###xml 460 466 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 4</italic>
###xml 472 480 421 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3p(E)-42</sub>
###xml 668 676 613 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3p(E)-42</sub>
###xml 683 687 625 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 694 698 633 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-42</sub>
###xml 708 717 644 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11p(E)-42</sub>
Binding specificity of pGlu Abeta (AbetapE3) antibodies. (a) Biacore analysis revealed that pGlu antibodies 2-48 (b) and 1-57 specifically bind to AbetapE3-38, not to Abeta3-38 and Abeta1-38. (c) The commercial antibody Abeta[N] recognizes only Abeta1-38, not Abeta3-38 or AbetapE3-38. (d) 2-48 and 1-57 recognize Abeta3p(E)-42, but not Abeta1-42, Abeta3-42, or Abeta11p(E)-42 under these conditions. Lane 1 Abeta1-42, Lane 2 Abeta3-42, Lane 3 Abeta11p(E)-42, Lane 4 Abeta3p(E)-42. 10 ng per well of each peptide was loaded on 3 separate 12% Bis-Tris gels, transferred to nitrocellulose and blotted with 1 mug/ml of each primary antibody. 2-48 and 1-57 recognize Abeta3p(E)-42, Abeta1-42, Abeta3-42, or Abeta11p(E)-42 under these conditions
###end p 31
###begin title 32
###xml 45 46 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 41 46 38 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-<italic>x</italic></sub>
Western blot showing specificity of AbetapE3-x antibodies 1-57 and 2-48
###end title 32
###begin p 33
###xml 120 126 114 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 228 230 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11</sub>
###xml 336 337 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 448 452 433 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2009</xref>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
In the presence of SDS and under denaturing conditions the two antibodies against pGlu Abeta specifically detected AbetapE3-42 without any visible cross-reactivity against other Abeta epitopes or pGlu epitope starting with Abeta11. The antibody HJ5.1 recognizes a central epitope of Abeta and therefore stains all peptides loaded (Fig. 2d). Staining specificity of transgenic mouse brain lysates using 2-48 has been shown previously (Wirths et al. 2009).
###end p 33
###begin title 34
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Dynamic changes of plaque-associated Abeta in the APP/PS1KI transgenic mouse brain
###end title 34
###begin p 35
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 169 174 166 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2008b</xref>
###xml 278 279 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 290 291 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 307 308 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 317 318 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 335 336 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 346 347 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 367 368 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 377 378 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 485 486 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 927 928 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 925 928 881 884 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 1014 1016 964 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE</sub>
###xml 1297 1303 1238 1244 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1400 1401 1341 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1426 1427 1367 1368 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1428 1429 1369 1370 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1542 1543 1477 1478 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1544 1545 1479 1480 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1729 1732 1655 1658 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1751 1752 1677 1678 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 1753 1754 1679 1680 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1766 1767 1692 1693 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1768 1769 1694 1695 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 1807 1816 1733 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1303 1824 1244 1749 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Plaque load analysis in APP/PS1KI mice. Plaque load was quantified at 2, 6 and 10&#160;months of age (<italic>n</italic>&#160;=&#160;5, female mice only). <bold>a</bold>&#8211;<bold>c</bold> A&#946;[N] an antibodies specific for position 1 of A&#946; showed a peak at six and a decline at 10&#160;months of age. <bold>d</bold>&#8211;<bold>f</bold> 4G8 recognizing A&#946; 17-24 showed an increase between 2 and 6&#160;month of age, while at 10&#160;months the plaque load did not increase any more. Analysis with the A&#946; pyroglutamate (A&#946;<sub>pE3</sub>) antibodies 2-48 (<bold>g</bold>&#8211;<bold>i</bold>) and 1-57 (<bold>j</bold>&#8211;<bold>l</bold>) demonstrated a continuous increase. <italic>Scale bar</italic> 200&#160;&#956;m</p>
###xml 1303 1824 1244 1749 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Plaque load analysis in APP/PS1KI mice. Plaque load was quantified at 2, 6 and 10&#160;months of age (<italic>n</italic>&#160;=&#160;5, female mice only). <bold>a</bold>&#8211;<bold>c</bold> A&#946;[N] an antibodies specific for position 1 of A&#946; showed a peak at six and a decline at 10&#160;months of age. <bold>d</bold>&#8211;<bold>f</bold> 4G8 recognizing A&#946; 17-24 showed an increase between 2 and 6&#160;month of age, while at 10&#160;months the plaque load did not increase any more. Analysis with the A&#946; pyroglutamate (A&#946;<sub>pE3</sub>) antibodies 2-48 (<bold>g</bold>&#8211;<bold>i</bold>) and 1-57 (<bold>j</bold>&#8211;<bold>l</bold>) demonstrated a continuous increase. <italic>Scale bar</italic> 200&#160;&#956;m</p></caption>
###xml 1824 1824 1749 1749 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_314_Fig3_HTML" id="MO3"/>
###xml 1297 1824 1238 1749 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="36">Plaque load analysis in APP/PS1KI mice. Plaque load was quantified at 2, 6 and 10&#160;months of age (<italic>n</italic>&#160;=&#160;5, female mice only). <bold>a</bold>&#8211;<bold>c</bold> A&#946;[N] an antibodies specific for position 1 of A&#946; showed a peak at six and a decline at 10&#160;months of age. <bold>d</bold>&#8211;<bold>f</bold> 4G8 recognizing A&#946; 17-24 showed an increase between 2 and 6&#160;month of age, while at 10&#160;months the plaque load did not increase any more. Analysis with the A&#946; pyroglutamate (A&#946;<sub>pE3</sub>) antibodies 2-48 (<bold>g</bold>&#8211;<bold>i</bold>) and 1-57 (<bold>j</bold>&#8211;<bold>l</bold>) demonstrated a continuous increase. <italic>Scale bar</italic> 200&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="702_2009_314_Fig3_HTML" id="MO3"/></fig>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 1337 1341 <span type="species:ncbi:10090">mice</span>
###xml 1414 1418 <span type="species:ncbi:10090">mice</span>
APP/PS1KI mice at 2, 6 and 10 months of age (Fig. 3) were stained with all four Abeta antibodies and plaque load was quantified as described earlier (Christensen et al. 2008b). One-way analysis of variance demonstrated significant differences between the groups using Abeta[N] (P < 0.0005; F = 19.39), 4G8 (P < 0.01; F = 14.77), 2-48 (P < 0.001; F = 20.67) and 1-57 (P < 0.01; F = 9.196). After Bonferroni correction (statistical significances between the groups are presented in Fig. 3) the mean values were as follows: Abeta[N] (mean +/- SEM at 2 months 1.7 +/- 0.2, 6 months 5.9 +/- 0.7 and 10 months 3 +/- 0.3); 4G8 (mean +/- SEM at 2 months 3.2 +/- 0.3, 6 months 9.6 +/- 0.6 and 10 months 9.1 +/- 1.2); 2-48 (mean +/- SEM at 2 months 0.2 +/- 0.1, 6 months 2.0 +/- 0.4 and 10 months 4.7 +/- 0.8); 1-57 (mean +/- SEM at 2 months 0.1 +/- 0.1, 6 months 0.8 +/- 0.2 and 10 months 2.9 +/- 0.9). While there was a peak of Abeta1-x at 6 months of age, total Abeta (4G8) reached a plateau at that time point, and AbetapE steadily increased from 2 to 10 months of age. These data indicate that (1) total Abeta plaque burden reaches a certain level of saturation, (2) Abeta starting at position 1 is degraded and/or truncated at later time points and (3) N-truncated pGlu Abeta is constantly increasing.Fig. 3Plaque load analysis in APP/PS1KI mice. Plaque load was quantified at 2, 6 and 10 months of age (n = 5, female mice only). a-c Abeta[N] an antibodies specific for position 1 of Abeta showed a peak at six and a decline at 10 months of age. d-f 4G8 recognizing Abeta 17-24 showed an increase between 2 and 6 month of age, while at 10 months the plaque load did not increase any more. Analysis with the Abeta pyroglutamate (AbetapE3) antibodies 2-48 (g-i) and 1-57 (j-l) demonstrated a continuous increase. Scale bar 200 mum
###end p 35
###begin p 36
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 239 240 233 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 241 242 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 426 429 411 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 448 449 433 434 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 450 451 435 436 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 463 464 448 449 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 465 466 450 451 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 504 513 489 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Plaque load analysis in APP/PS1KI mice. Plaque load was quantified at 2, 6 and 10 months of age (n = 5, female mice only). a-c Abeta[N] an antibodies specific for position 1 of Abeta showed a peak at six and a decline at 10 months of age. d-f 4G8 recognizing Abeta 17-24 showed an increase between 2 and 6 month of age, while at 10 months the plaque load did not increase any more. Analysis with the Abeta pyroglutamate (AbetapE3) antibodies 2-48 (g-i) and 1-57 (j-l) demonstrated a continuous increase. Scale bar 200 mum
###end p 36
###begin title 37
Comparison of Abeta plaque load in sporadic and familial AD brain
###end title 37
###begin p 38
###xml 34 35 34 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 590 591 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 873 874 867 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1356 1357 1347 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1354 1357 1345 1348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 1394 1397 1382 1385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1664 1667 1646 1649 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1903 1909 1879 1885 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1979 1990 1955 1966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Upper panel</italic>
###xml 2134 2135 2098 2099 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2136 2137 2100 2101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2234 2246 2195 2207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Middle panel</italic>
###xml 2404 2405 2365 2366 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2406 2407 2367 2368 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2410 2421 2371 2382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lower panel</italic>
###xml 2545 2546 2503 2504 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 2547 2548 2505 2506 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 2551 2560 2509 2518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 1909 2568 1885 2525 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Staining pattern in frontal cortex of sporadic and familial AD brain. <italic>Upper panel</italic> showing the staining pattern in a sporadic AD case using 4G8 (A&#946; 17-24), 2-48 (pGlu A&#946;) and A&#946;[N] (specific for A&#946; at position 1) (<bold>a</bold>&#8211;<bold>c</bold>). While the staining pattern of 4G8 and 2-48 is comparable, there is no staining with A&#946;[N]. <italic>Middle panel</italic> comparable levels of plaque load with all three antibodies in a FAD case with the Swedish mutation. Note abundant vessel staining with all three antibodies (<bold>d</bold>&#8211;<bold>f</bold>). <italic>Lower panel</italic> the same is true for the staining pattern in a case with the arctic mutation; however, A&#946;[N] staining is less abundant (<bold>g</bold>&#8211;<bold>i</bold>). <italic>Scale bar</italic> 200&#160;&#956;m</p>
###xml 1909 2568 1885 2525 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Staining pattern in frontal cortex of sporadic and familial AD brain. <italic>Upper panel</italic> showing the staining pattern in a sporadic AD case using 4G8 (A&#946; 17-24), 2-48 (pGlu A&#946;) and A&#946;[N] (specific for A&#946; at position 1) (<bold>a</bold>&#8211;<bold>c</bold>). While the staining pattern of 4G8 and 2-48 is comparable, there is no staining with A&#946;[N]. <italic>Middle panel</italic> comparable levels of plaque load with all three antibodies in a FAD case with the Swedish mutation. Note abundant vessel staining with all three antibodies (<bold>d</bold>&#8211;<bold>f</bold>). <italic>Lower panel</italic> the same is true for the staining pattern in a case with the arctic mutation; however, A&#946;[N] staining is less abundant (<bold>g</bold>&#8211;<bold>i</bold>). <italic>Scale bar</italic> 200&#160;&#956;m</p></caption>
###xml 2568 2568 2525 2525 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_314_Fig4_HTML" id="MO4"/>
###xml 1903 2568 1879 2525 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="39">Staining pattern in frontal cortex of sporadic and familial AD brain. <italic>Upper panel</italic> showing the staining pattern in a sporadic AD case using 4G8 (A&#946; 17-24), 2-48 (pGlu A&#946;) and A&#946;[N] (specific for A&#946; at position 1) (<bold>a</bold>&#8211;<bold>c</bold>). While the staining pattern of 4G8 and 2-48 is comparable, there is no staining with A&#946;[N]. <italic>Middle panel</italic> comparable levels of plaque load with all three antibodies in a FAD case with the Swedish mutation. Note abundant vessel staining with all three antibodies (<bold>d</bold>&#8211;<bold>f</bold>). <italic>Lower panel</italic> the same is true for the staining pattern in a case with the arctic mutation; however, A&#946;[N] staining is less abundant (<bold>g</bold>&#8211;<bold>i</bold>). <italic>Scale bar</italic> 200&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="702_2009_314_Fig4_HTML" id="MO4"/></fig>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 405 410 <span type="species:ncbi:9606">Human</span>
###xml 1062 1067 <span type="species:ncbi:9606">human</span>
###xml 1109 1113 <span type="species:ncbi:10090">mice</span>
###xml 1244 1248 <span type="species:ncbi:10090">mice</span>
###xml 1305 1309 <span type="species:ncbi:10090">mice</span>
###xml 1425 1429 <span type="species:ncbi:10090">mice</span>
The plaque staining pattern (Fig. 1), BIAcore and Western blot analysis (Fig. 2) together with the staining pattern in the APP/PS1KI mice (Fig. 3) revealed that the specificity and affinity of the antibodies 1-57 and 2-48 was very similar under native and denaturing conditions. Therefore, only 2-48 was used as an additional antibody for confirmation of findings obtained with the following experiments. Human postmortem brain tissue (frontal cortex from sporadic AD, FAD and non-demented individuals) was used to compare staining patterns obtained with this set of Abeta antibodies (Fig. 4). Most of the sporadic and all of the familial AD (FAD) cases demonstrated high abundance and similar amount of plaques stained with 4G8 and 2-48. Plaques stained with Abeta[N] were less frequently observed. We also identified cases with similar staining using 4G8 and 2-48 (Table 1) indicating that N-terminal truncation has occurred. While the plaque load per se did not differ between non-demented controls and AD cases, it is interesting to note that the pattern in human cases resembled the pattern in APP/PS1KI mice. For example, case AD 5 demonstrated low plaque load according to all three antibodies resembling the pattern seen in 2-month-old mice. The case AD 9 showed a pattern as seen in 10-month-old mice. Interestingly, we never observed high Abeta1-x levels in combination with low AbetapE3 reaction as in 6-month-old mice. All three antibodies stained Abeta in blood vessels, a typical feature of congophilic angiopathy (CAA). We did not observe any correlation between Braak staging and plaque pathology. Interestingly, all FAD cases showed abundant AbetapE3 plaques. The FAD cases having an APP Swedish (APP swe) or APP arctic (APP arc) mutation demonstrated a similar extent of Abeta plaque load. The Presenilin-1 case with P264L mutation had only a minor amount of Abeta[N] positive plaques.Fig. 4Staining pattern in frontal cortex of sporadic and familial AD brain. Upper panel showing the staining pattern in a sporadic AD case using 4G8 (Abeta 17-24), 2-48 (pGlu Abeta) and Abeta[N] (specific for Abeta at position 1) (a-c). While the staining pattern of 4G8 and 2-48 is comparable, there is no staining with Abeta[N]. Middle panel comparable levels of plaque load with all three antibodies in a FAD case with the Swedish mutation. Note abundant vessel staining with all three antibodies (d-f). Lower panel the same is true for the staining pattern in a case with the arctic mutation; however, Abeta[N] staining is less abundant (g-i). Scale bar 200 mum
###end p 38
###begin p 39
###xml 70 81 70 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Upper panel</italic>
###xml 225 226 213 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 227 228 215 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 325 337 310 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Middle panel</italic>
###xml 495 496 480 481 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 497 498 482 483 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 501 512 486 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lower panel</italic>
###xml 636 637 618 619 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 638 639 620 621 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 642 651 624 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
Staining pattern in frontal cortex of sporadic and familial AD brain. Upper panel showing the staining pattern in a sporadic AD case using 4G8 (Abeta 17-24), 2-48 (pGlu Abeta) and Abeta[N] (specific for Abeta at position 1) (a-c). While the staining pattern of 4G8 and 2-48 is comparable, there is no staining with Abeta[N]. Middle panel comparable levels of plaque load with all three antibodies in a FAD case with the Swedish mutation. Note abundant vessel staining with all three antibodies (d-f). Lower panel the same is true for the staining pattern in a case with the arctic mutation; however, Abeta[N] staining is less abundant (g-i). Scale bar 200 mum
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 77 80 74 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 318 321 312 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 384 388 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 441 444 432 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 505 506 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 503 506 491 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 622 625 607 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 688 689 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 686 689 668 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 910 916 886 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 1076 1080 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2009</xref>
###xml 1229 1233 1202 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">1995</xref>
###xml 1389 1393 1359 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2009</xref>
###xml 1612 1615 1579 1582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1771 1773 1735 1737 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3E</sub>
###xml 1870 1874 1834 1838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2009</xref>
###xml 2040 2046 2001 2007 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 2200 2203 2155 2158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 2243 2249 2195 2201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 2446 2450 2398 2402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2009</xref>
###xml 2465 2469 2417 2421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2004</xref>
###xml 2511 2516 2463 2468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2008b</xref>
###xml 2574 2579 2526 2531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2008a</xref>
###xml 2692 2698 2641 2647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 1045 1060 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1637 1641 <span type="species:ncbi:10090">mice</span>
###xml 1739 1754 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1844 1849 <span type="species:ncbi:10090">mouse</span>
###xml 1938 1942 <span type="species:ncbi:10090">mice</span>
###xml 2102 2106 <span type="species:ncbi:10090">mice</span>
###xml 2306 2311 <span type="species:ncbi:10090">mouse</span>
###xml 2377 2381 <span type="species:ncbi:10090">mice</span>
###xml 2637 2642 <span type="species:ncbi:10090">mouse</span>
In the present work, we show that large numbers of plaques positive for AbetapE3 are present in patients with sporadic AD as has been shown earlier using two novel antibodies. In addition, we demonstrate that also familial AD including those carrying mutations in APP (arctic and Swedish) and PS1 harbor abundant AbetapE3plaques. In contrast to a recent publication (Schilling et al. 2008), we observed that control cases also harbored AbetapE3 positive plaques. The amount of plaques positive for Abeta1-x is less abundant in the control cases. Interestingly, in APP/PS1KI mice, we observed a continuous increase in AbetapE3 plaque load with increasing age, while the density for Abeta1-x plaques declined with aging. We therefore assume that, in particular, the peptides starting with position 1 of Abeta are N-truncated as disease progresses. On the other side, we have demonstrated that intraneuronal AbetapE3-42 expression is highly toxic in vivo, and that the induced neuron loss is associated with a lethal neurological phenotype in TBA2 transgenic mice (Wirths et al. 2009). Saido et al. suggested that the removal of N-terminal amino acids 1 and 2 of Abeta could be carried out by a hypothetical peptidase (Saido et al. 1995), and very recently it has been shown that aminopeptidase A may be responsible for the N-terminal truncation of full-length Abeta peptides (Sevalle et al. 2009). If a subsequent glutamate cyclization by a glutamate cyclase occurs leading to pGlu formation, this could protect the peptide from degradation and even make it more prone to accumulate. The increasing levels of AbetapE3 plaques in APP/PS1KI mice with age could be due to this effect. To further verify this in vivo, we have recently generated transgenic mice expressing Abeta3E starting at position 3 with glutamine and ending at position 42 (TBA2 mouse line (Wirths et al. 2009)). The severity of the neurological phenotype observed in TBA2 mice, accompanied by Purkinje cell loss and premature mortality reflects the in vivo toxicity of AbetapE3-42. Interestingly, 85% of Abeta peptides in the APP/PS1KI mice terminated at position 42, whereas the N-terminus shows a large heterogeneity including AbetapE3. The time point of high levels of AbetapE3-42 coincided with the onset of behavioral deficits in both mouse models. We have previously shown that at 6 months, the APP/PS1KI mice exhibit a neuron loss in CA1 of the hippocampus (Breyhan et al. 2009; Casas et al. 2004), the frontal cortex (Christensen et al. 2008b), and in distinct cholinergic nuclei (Christensen et al. 2008a). Overall, the pathological events seen in the APP/PS1KI mouse model might be at least partly triggered by AbetapE3-42 accumulation.
###end p 41
###begin p 42
N-terminal truncation of Abeta seems to be a common phenomenon in brain material that has been stored for a long time. In brain material that has been stored only a few years, much more N-terminally intact Abeta is found. The conclusion from this preliminary study is that the process of N-terminal truncation might continue while the brain tissue is kept at -80degreesC (Lars Lannfelt and Martin Ingelsson, unpublished data). This phenomenon is not likely to occur in paraffin-embedded tissue. However, it cannot be completely ruled out.
###end p 42
###begin p 43
###xml 17 20 14 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 100 104 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2006</xref>
###xml 122 126 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2000</xref>
###xml 142 146 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1998</xref>
###xml 164 168 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1996</xref>
###xml 181 185 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">1997</xref>
###xml 187 191 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2001</xref>
###xml 210 214 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2005</xref>
###xml 228 232 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">1992</xref>
###xml 249 253 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2005</xref>
###xml 255 259 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2007</xref>
###xml 274 278 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">1997</xref>
###xml 293 297 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">1995</xref>
###xml 299 303 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">1996</xref>
###xml 321 325 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">1998</xref>
###xml 429 433 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1995</xref>
###xml 441 444 432 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 496 500 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1999</xref>
###xml 519 523 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2006</xref>
###xml 552 556 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1998</xref>
###xml 635 639 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2002</xref>
###xml 786 793 768 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40/42</sub>
###xml 808 812 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2001</xref>
###xml 1096 1100 1078 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2006</xref>
###xml 1375 1378 1354 1357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1552 1555 1528 1531 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1742 1748 1715 1721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3-42</sub>
###xml 1908 1912 1881 1885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2009</xref>
###xml 2093 2097 2063 2067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 2184 2187 2151 2154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 2424 2427 2388 2391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 2451 2455 2415 2419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2006</xref>
###xml 2487 2491 2451 2455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 2731 2735 2692 2696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2009</xref>
###xml 2943 2946 2898 2901 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 3114 3117 3066 3069 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 3174 3176 3126 3128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 3183 3184 3135 3136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3273 3276 3222 3225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 3520 3523 3466 3469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 3576 3579 3519 3522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 3673 3676 3613 3616 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 3887 3888 3821 3822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 3885 3888 3819 3822 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 1806 1810 <span type="species:ncbi:10090">mice</span>
###xml 2809 2817 <span type="species:ncbi:9606">patients</span>
###xml 2985 2993 <span type="species:ncbi:9606">patients</span>
###xml 3047 3055 <span type="species:ncbi:9606">patients</span>
###xml 3485 3493 <span type="species:ncbi:9606">patients</span>
N-truncated AbetapE3 peptides have been identified by several groups from AD brains (Guntert et al. 2006; Harigaya et al. 2000; Hosoda et al. 1998; Iwatsubo et al. 1996; Kuo et al. 1997, 2001; Miravalle et al. 2005; Mori et al. 1992; Piccini et al. 2005, 2007; Russo et al. 1997; Saido et al. 1995, 1996; Tekirian et al. 1998). N-terminal deletions, in general, enhance aggregation of beta-amyloid peptides in vitro (Pike et al. 1995). AbetapE3 has a higher aggregation propensity (He and Barrow 1999; Schilling et al. 2006), and stability (Kuo et al. 1998), and shows an increased toxicity compared to full-length Abeta (Russo et al. 2002). It has been suggested that N-truncated Abeta peptides are formed directly by BACE and not through a progressive proteolysis of full-length Abeta1-40/42 (Russo et al. 2001). In our view this concept is not likely to be the explanation of the present data, because the increase in pyroglutamate formation appeared to happen on the expense of full-length N-terminal Abeta. Our data are in good agreement with a previously published paper by Guntert et al. (2006). It was found that in cored plaques there was an increase of N-terminal truncations of approximately 20% between Braak stages IV-VI. In contrast, diffuse plaques of AD and control cases showed consistently only low levels of amino-terminal truncations. Whether or not AbetapE3 is acting as a seed for plaque formation is a matter of current scientific debate. Up to now there is no sufficient proof (or disproof) that this is actually the case. AbetapE3 formation (in plaques) appears to be a late process involved in the maturation of plaques rather than in the seeding of plaques. On the other side, it is obvious that intraneuronal AbetapE3-42 accumulation initiates an early lethal phenotype in TBA2 mice associated with massive neuron loss, atrophy and neurological behavioral deficits (Wirths et al. 2009). In in vitro experiments Schilling et al. have shown that cyclization of glutamate at position 3 of Abeta can be driven enzymatically by glutaminyl cyclase (QC) (Schilling et al. 2004). In addition, it has been demonstrated that QC inhibition significantly reduced AbetapE3 formation, emphasizing the importance of QC activity during cellular maturation of pyroglutamate-containing peptides. The pharmacological inhibition of QC activity by the QC inhibitor P150, which significantly reduced the level of AbetapE3 in vitro (Cynis et al. 2006) and in vivo (Schilling et al. 2008), suggests that QC inhibition might serve as a new therapeutic approach. In addition, we have investigated the level of IgM autoantibodies directed against different Abeta epitopes as potential diagnostic biomarker for AD (Marcello et al. 2009). Anti-Abeta autoantibody levels were measured in 75 plasma samples from patients with AD, individuals with mild cognitive impairment (MCI), and healthy age- and sex-matched controls. The mean level of AbetapE3-IgM was significantly decreased in AD patients as compared to healthy controls. In the group of MCI patients there was a significant positive correlation between AbetapE3-IgM and cognitive decline analyzed by MMSE (rho = 0.58, df = 13, P = 0.022). These observations indicate that the level of IgM autoantibodies against AbetapE3 is a promising plasma biomarker for AD and correlates with the cognitive status of individuals at risk to develop AD. It is, however, tempting to speculate that the correlation of the cognitive status in MCI patients with lower levels of AbetapE3-IgM in plasma might be due to early changes in AbetapE3-induced neurodegeneration prior to clinical diagnosis of AD. Overall, the importance of AbetapE3 in AD pathology is an issue of increasing interest. We believe that the present manuscript adds further evidence that N-terminal pE-modified Abeta in plaques is continuously increasing on the expense of Abeta1-x. The consequences of continuous rearrangement of plaque Abeta by pyroglutamate formation are presently unclear.
###end p 43
###begin p 44
###xml 269 273 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2008</xref>
###xml 346 350 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2001</xref>
###xml 364 367 355 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 391 395 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2006</xref>
###xml 585 588 573 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3pE</sub>
###xml 782 786 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2007</xref>
###xml 897 901 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2002</xref>
###xml 917 921 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2000</xref>
###xml 1023 1027 1002 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2004</xref>
###xml 1113 1117 1092 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">2004</xref>
###xml 1136 1140 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">2002</xref>
###xml 1383 1387 1359 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">2004</xref>
###xml 1569 1573 1542 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 1653 1656 1623 1626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1788 1792 1758 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2006</xref>
###xml 1913 1916 1880 1883 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 1940 1944 1907 1911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2006</xref>
###xml 1976 1980 1943 1947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 2067 2070 2031 2034 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 218 223 <span type="species:ncbi:9606">human</span>
###xml 291 296 <span type="species:ncbi:10090">mouse</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
###xml 871 876 <span type="species:ncbi:9606">human</span>
###xml 1319 1323 <span type="species:ncbi:10090">mice</span>
###xml 1350 1355 <span type="species:ncbi:9606">human</span>
Animal models aim to replicate the symptoms, the lesions or the cause(s) of Alzheimer disease. Mutated human APP expression results in the deposition of Abeta peptide, similar but not identical to the Abeta peptide of human senile plaque (reviewed in Duyckaerts et al. 2008). APP transgenic mouse models have been reported to show no (Kuo et al. 2001) or low AbetapE3 levels (Guntert et al. 2006). Maeda et al. have demonstrated that the localization and abundance of [11C]PIB autoradiographic signals were closely associated with those of amino-terminally truncated and modified Abeta3pE deposition in AD and different APP transgenic mouse brains, implying that the detectability of amyloid by [11C]PIB-PET is dependent on the accumulation of specific Abeta subtypes (Maeda et al. 2007). An emerging role of intracellular Abeta accumulation has been previously shown in human AD (D'Andrea et al. 2002; Gouras et al. 2000) while it has been observed that Abeta localizes predominantly to abnormal endosomes (Cataldo et al. 2004), multivesicular bodies and within pre- and postsynaptic compartments (Langui et al. 2004; Takahashi et al. 2002). Takahashi et al. demonstrated that Abeta42 aggregates into oligomers within endosomal vesicles and along microtubules of neuronal processes, both in cultured neurons of Tg2576 mice, as well as in Tg2576 and human AD brain (Takahashi et al. 2004). In in vitro experiments, Schilling et al. have shown that cyclization of glutamate at position 3 of Abeta can be driven enzymatically by glutaminyl cyclase (QC) (Schilling et al. 2004). In addition, it has been shown that QC inhibition significantly reduced AbetapE3 formation, emphasizing the importance of QC activity during cellular maturation of pyroglutamate-containing peptides (Cynis et al. 2006). The pharmacological inhibition of QC activity by the QC inhibitor P150, which significantly reduced the level of AbetapE3 in vitro (Cynis et al. 2006) and in vivo (Schilling et al. 2008) suggests that QC inhibition might serve as a new therapeutic approach to rescue AbetapE3 triggered neurodegeneration in AD.
###end p 44
###begin p 45
###xml 36 39 33 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 153 156 147 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 256 257 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 254 257 242 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-<italic>x</italic></sub>
###xml 438 442 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2009</xref>
###xml 495 498 480 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 666 669 645 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-x</sub>
###xml 843 846 819 822 <sub xmlns:xlink="http://www.w3.org/1999/xlink">pE3</sub>
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
In summary, we have shown that AbetapE3 plaques are abundant in sporadic and familial AD cases, and that at least in the APP/PS1KI mouse model, the AbetapE3 plaque load increases in an age-dependent manner, which is not the case for total Abeta and Abeta1-x. Most recently, it has been shown that plaque load in non-demented individuals constantly increases with aging, while it decreases in AD patients older than 95 years (Savva et al. 2009). At present there is a lack of information on AbetapE3 plaque load in such a cohort of individuals. It would be interesting to study the heterogeneity of N-terminal variant Abeta peptides, since we observed that only Abeta1-x plaques declined with aging in the APP/PS1KI mice and were less frequent in sporadic and familial AD cases. It is tempting to speculate that the continuous increase in AbetapE3 between 6 and 10 months in APP/PS1KI mice is due to a corresponding truncation of full-length Abeta-peptides, as the overall plaque load, as shown by 4G8 staining, is stable in that time period. Future studies will provide a better understanding of the consequence of N-truncated Abeta for AD progression.
###end p 45
###begin p 46
This work was supported by the European Commission, Marie Curie Early Stage Training, MEST-CT-2005-020013 (NEURAD), Alzheimer PhD Graduate School.
###end p 46
###begin p 47
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 47
###begin title 48
References
###end title 48
###begin article-title 49
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice
###end article-title 49
###begin article-title 50
###xml 18 22 <span type="species:ncbi:10090">mice</span>
APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
###end article-title 50
###begin article-title 51
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated A{beta}42 accumulation in a novel Alzheimer transgenic model
###end article-title 51
###begin article-title 52
Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome
###end article-title 52
###begin article-title 53
###xml 136 140 <span type="species:ncbi:10090">mice</span>
Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice
###end article-title 53
###begin article-title 54
Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells
###end article-title 54
###begin article-title 55
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta
###end article-title 55
###begin article-title 56
Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex
###end article-title 56
###begin article-title 57
###xml 29 34 <span type="species:ncbi:9606">human</span>
Alzheimer disease models and human neuropathology: similarities and differences
###end article-title 57
###begin article-title 58
Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies
###end article-title 58
###begin article-title 59
###xml 38 43 <span type="species:ncbi:9606">human</span>
Intraneuronal Abeta42 accumulation in human brain
###end article-title 59
###begin article-title 60
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain
###end article-title 60
###begin article-title 61
Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain
###end article-title 61
###begin article-title 62
Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity
###end article-title 62
###begin article-title 63
The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta
###end article-title 63
###begin article-title 64
###xml 40 55 <span type="species:ncbi:10090">transgenic mice</span>
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
###end article-title 64
###begin article-title 65
###xml 22 37 <span type="species:ncbi:10090">transgenic mice</span>
Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits
###end article-title 65
###begin article-title 66
Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains
###end article-title 66
###begin article-title 67
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
###end article-title 67
###begin article-title 68
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques
###end article-title 68
###begin article-title 69
###xml 4 19 <span type="species:ncbi:10090">transgenic mice</span>
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques
###end article-title 69
###begin article-title 70
Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets
###end article-title 70
###begin article-title 71
Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits
###end article-title 71
###begin article-title 72
Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Abeta peptides of Alzheimer's disease
###end article-title 72
###begin article-title 73
###xml 100 105 <span type="species:ncbi:10090">mouse</span>
Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains
###end article-title 73
###begin article-title 74
###xml 62 77 <span type="species:ncbi:10090">transgenic mice</span>
Subcellular topography of neuronal A{beta} peptide in APPxPS1 transgenic mice
###end article-title 74
###begin article-title 75
###xml 106 111 <span type="species:ncbi:10090">mouse</span>
Longitudinal, quantitative assesment of amyloid, neuroinflammation and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by PET
###end article-title 75
###begin article-title 76
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels
###end article-title 76
###begin article-title 77
Amyloid plaque core protein in Alzheimer disease and Down syndrome
###end article-title 77
###begin article-title 78
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
###end article-title 78
###begin article-title 79
###xml 75 81 <span type="species:ncbi:3635">cotton</span>
Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques
###end article-title 79
###begin article-title 80
###xml 28 43 <span type="species:ncbi:10090">transgenic mice</span>
Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
###end article-title 80
###begin article-title 81
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease
###end article-title 81
###begin article-title 82
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline
###end article-title 82
###begin article-title 83
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation
###end article-title 83
###begin article-title 84
{beta}-Amyloid is different in normal aging and in Alzheimer disease
###end article-title 84
###begin article-title 85
Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype
###end article-title 85
###begin article-title 86
Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro
###end article-title 86
###begin article-title 87
###xml 89 104 <span type="species:ncbi:10090">transgenic mice</span>
Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice
###end article-title 87
###begin article-title 88
Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains
###end article-title 88
###begin article-title 89
Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain
###end article-title 89
###begin article-title 90
Pyroglutamate-modified amyloid-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival
###end article-title 90
###begin article-title 91
Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques
###end article-title 91
###begin article-title 92
###xml 81 86 <span type="species:ncbi:9606">human</span>
Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain
###end article-title 92
###begin article-title 93
Age, neuropathology, and dementia
###end article-title 93
###begin article-title 94
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions
###end article-title 94
###begin article-title 95
On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)
###end article-title 95
###begin article-title 96
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology
###end article-title 96
###begin article-title 97
The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease
###end article-title 97
###begin article-title 98
Alzheimer's disease: genes, proteins, and therapy
###end article-title 98
###begin article-title 99
Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease
###end article-title 99
###begin article-title 100
Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide
###end article-title 100
###begin article-title 101
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology
###end article-title 101
###begin article-title 102
Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain
###end article-title 102
###begin article-title 103
N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits
###end article-title 103
###begin article-title 104
Amyloid beta-peptide: the inside story
###end article-title 104
###begin article-title 105
###xml 89 94 <span type="species:ncbi:9606">human</span>
The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain
###end article-title 105
###begin article-title 106
Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration
###end article-title 106
###begin article-title 107
###xml 108 123 <span type="species:ncbi:10090">transgenic mice</span>
Intraneuronal APP/Abeta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice
###end article-title 107
###begin article-title 108
A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade
###end article-title 108
###begin article-title 109
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Age-dependent axonal degeneration in an Alzheimer mouse model
###end article-title 109
###begin article-title 110
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease
###end article-title 110
###begin article-title 111
###xml 115 120 <span type="species:ncbi:10090">mouse</span>
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
###end article-title 111

